No Data
Leerink Partners Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $7
Promising Potential of Trevi Therapeutics' Haduvio in IPF Cough Drives Buy Rating Amid RCC Challenges
Needham Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $8
What Makes Trevi Therapeutics (TRVI) a New Buy Stock
Express News | Trevi Therapeutics Announced Business Updates Ahead Of Its Participation In The 14th Annual Lifesci Partners Corporate Access Event Taking Place In San Francisco, Ca, From January 13-15, 2025
B.Riley Financial Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $11
s
